Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.30 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.30 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26627886 | 0.89 | CHRNA7 (0.35) | CHRNA7CYP2D6KDM4EALDH1A1MAPT | |
| SCHEMBL20684606 | 0.89 | SIGMAR1 (0.34) | CHRNA7CYP2D6KDM4EALDH1A1MAPT | |
| SCHEMBL1106901 | 0.83 | — | — | |
| SCHEMBL13290568 | 0.83 | CHRNA7 (0.46) | CHRNA7CYP2D6KDM4EALDH1A1MAPT | |
| SCHEMBL681912 | 0.83 | CHRNA7 (0.46) | CHRNA7CYP2D6KDM4EALDH1A1MAPT | |
| SCHEMBL6660188 | 0.83 | CHRNA7 (0.46) | CHRNA7CYP2D6KDM4EALDH1A1MAPT | |
| SCHEMBL13290580 | 0.83 | CHRNA7 (0.46) | CHRNA7CYP2D6KDM4EALDH1A1MAPT | |
| SCHEMBL13290572 | 0.83 | CHRNA7 (0.46) | CHRNA7CYP2D6KDM4EALDH1A1MAPT | |
| SCHEMBL13117824 | 0.82 | — | — | |
| Pyridine SCHEMBL28229191 | 0.80 | CYP2D6 (0.39) | CYP2D6KDM4EALDH1A1MAPTPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1451185-B1 | INDOLE-2-CARBOXAMIDES AS FACTOR XA INHIBITORS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2014-08-06 | — | — | EP | claimed |
| JP-2005514365-A | — | — | 2005-05-19 | — | — | JP | claimed |
| US-20050043302-A1 | New indole derivatives as factor Xa inhibitors | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-02-24 | — | — | US | claimed |
| EP-1451185-A1 | INDOLE-2-CARBOXAMIDES AS FACTOR XA INHIBITORS | Aventis Pharma Deutschland GmbH (DE) | 2004-09-01 | — | — | EP | claimed |
| US-20030199689-A1 | New indole derivatives as factor Xa inhibitors | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2003-10-23 | — | — | US | claimed |
| WO-2003044014-A1 | INDOLE-2-CARBOXAMIDES AS FACTOR XA INHIBITORS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-05-30 | — | — | WO | claimed |
| WO-2023223055-A1 | ANTI-VIRAL COMPOUNDS | Infex Therapeutics Limited (GB) | 2023-11-23 | — | — | WO | disclosed |
| US-11731987-B2 | Prolyl hydroxylase domain-containing protein (PHD) inhibitors and uses thereof | INSILICO MEDICINE IP LIMITED (HK) | 2023-08-22 | — | — | US | disclosed |
| US-11731987-B2 | Prolyl hydroxylase domain-containing protein (PHD) inhibitors and uses thereof | INSILICO MEDICINE IP LIMITED (HK) | 2023-08-22 | — | — | US | disclosed |
| US-20230203063-A1 | TRICYCLIC PYRIDONES AND PYRIMIDONES | ERASCA, INC. | 2023-06-29 | — | — | US | disclosed |
| WO-2022058745-A9 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AND THEIR USE IN THERAPY | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2022-05-27 | — | — | WO | disclosed |
| WO-2022090481-A1 | SUBSTITUTED 1H-PYRAZOLO[4,3-C]PYRIDINES AND DERIVATIVES AS EGFR INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-05-05 | — | — | WO | disclosed |
| WO-2022058745-A2 | NOVEL COMPOUNDS AND THEIR USE IN THERAPY | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2022-03-24 | — | — | WO | disclosed |
| WO-2009010555-A1 | NEW DRUGS WITH ANTICHOLESTATIC ACTIVITY | SEGIX ITALIA S.R.L. (IT) | 2009-01-22 | — | — | WO | disclosed |
| US-6906084-B2 | Indole derivatives as factor Xa inhibitors | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-06-14 | — | — | US | disclosed |
| US-20050043302-A1 | New indole derivatives as factor Xa inhibitors | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-02-24 | — | — | US | disclosed |
| EP-1451185-A1 | INDOLE-2-CARBOXAMIDES AS FACTOR XA INHIBITORS | Aventis Pharma Deutschland GmbH (DE) | 2004-09-01 | — | — | EP | disclosed |
| US-20030199689-A1 | New indole derivatives as factor Xa inhibitors | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2003-10-23 | — | — | US | disclosed |
| WO-2003044014-A1 | INDOLE-2-CARBOXAMIDES AS FACTOR XA INHIBITORS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-05-30 | — | — | WO | disclosed |
| EP-0903346-A1 | SYDNONE IMINE DERIVATIVES | Chugai Seiyaku Kabushiki Kaisha (JP) | 1999-03-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203063-A1 | TRICYCLIC PYRIDONES AND PYRIMIDONES | TYMS, TYMP, DHFR | CHRNA7 2696/4885CYP2D6 9/4885KDM4E 3587/4885 |
| US-11731987-B2 | Prolyl hydroxylase domain-containing protein (PHD) inhibitors and uses thereof | EGLN3, EGLN2, EGLN1 | CHRNA7 4870/4885CYP2D6 3773/4885KDM4E 127/4885 |
| US-20030199689-A1 | New indole derivatives as factor Xa inhibitors | F5, F12, F2 | CHRNA7 2384/4885CYP2D6 257/4885KDM4E 1206/4885 |
| US-20050043302-A1 | New indole derivatives as factor Xa inhibitors | F12, F5, F2 | CHRNA7 1672/4885CYP2D6 477/4885KDM4E 1584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.